Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir and Elbasvir in HCV with CKD (C-SURFER)
NCT02092350Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of grazoprevir and elbasvir in hepatitis C (HCV) (3 arms), sponsored by Merck & Co. Primary endpoints: Sustained Virologic Response 12 Weeks After Completing Study Therapy, Number of Participants Experiencing an Adverse Event and 1 more. Started Mar 2014; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02092350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02092350.